Table 1.

Baseline characteristics of patients switching from Etanercept (Enbrel^®) to SB4 (Benepali^®) at Blackpool Teaching Hospitals NHS Foundation Trust

	Rheumatoid arthritis	Axial Spondyloarthropathy	Psoriatic arthritis
Number, n	36	23	13
Female, n (%)	27 (75%)	7 (30%)	6 (46%)
Age, years	62 (56–77)	56 (46–66)	54 (51.5–67.5)
Duration on Etanercept before switching to SB4, years	3.8 (2.3–7.5)	5.2 (3.1–7.5)	2.8 (2.3–6.6)
Duration on Etanercept of patients in clinical remission before switching to SB4, years	5.4 (4.3–7.1)	5.7 (2.9–7.2)	3.3 (2.5–6.4)
Duration of disease before switching to SB4, years	15 (8.2–21)	29 (17.3–38)	17 (12.5–26.5)
Co- treatment with DMARDs, n (%)	32 (89%)	2 (8,7%)	9 (69.2%)
Concominant Methotrexate, n (%)	26 (72%)	1 (4,3%)	6 (46.2%)
On other bDMARDs before Etanercept, n (%)	8 (22.2%)	4 (17.4%)	2 (15.4%)
DAS- 28 before any bDMARD	6.18 (5.72–6.71)	NA	NA
DAS- 28 before switching to SB4	2.87 (1.89–3.73)	NA	NA
BASDAI before any bDMARD	NA	7.01 (6.25–8.68)	NA
BASDAI before switching to SB4	NA	2.95 (1.94–4.85)	NA
Number of tender joints, n	1.00 (0.00–4.00)	0.00 (0.00–0.00)	1.00 (0.00–2.50)
Number of swollen joints, n	1.00 (0.00–2.00)	0.00 (0.00–0.00)	1.00 (0.00–2.00)
ESR before switching to SB4, mm/hr	12.50 (6.00–19.75)	6.00 (2.00–9.00)	7.00 (5.00–26.50)
CRP before switching to SB4, mg/dl	2.00 (1.00–5.00)	4.00 (1.00–7.90)	2.00 (1.00–9.50)

Numbers are medians (interquartile ranges). bDMARDs= biological DMARDs, NA= Not Applicable